Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.08
MDCO's Cash to Debt is ranked lower than
60% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MDCO: 1.08 )
Ranked among companies with meaningful Cash to Debt only.
MDCO' s 10-Year Cash to Debt Range
Min: 1.08  Med: 10000.00 Max: No Debt
Current: 1.08
Equity to Asset 0.44
MDCO's Equity to Asset is ranked lower than
76% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MDCO: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MDCO' s 10-Year Equity to Asset Range
Min: 0.44  Med: 0.77 Max: 0.89
Current: 0.44
0.44
0.89
F-Score: 3
Z-Score: 1.53
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -13.51
MDCO's Operating margin (%) is ranked lower than
82% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. MDCO: -13.51 )
Ranked among companies with meaningful Operating margin (%) only.
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44  Med: -4.69 Max: 14.87
Current: -13.51
-401.44
14.87
Net-margin (%) -3.29
MDCO's Net-margin (%) is ranked lower than
76% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. MDCO: -3.29 )
Ranked among companies with meaningful Net-margin (%) only.
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2  Med: -3.45 Max: 29.79
Current: -3.29
-385.2
29.79
ROE (%) -2.39
MDCO's ROE (%) is ranked lower than
73% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. MDCO: -2.39 )
Ranked among companies with meaningful ROE (%) only.
MDCO' s 10-Year ROE (%) Range
Min: -339.01  Med: -3.55 Max: 35
Current: -2.39
-339.01
35
ROA (%) -1.16
MDCO's ROA (%) is ranked lower than
71% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MDCO: -1.16 )
Ranked among companies with meaningful ROA (%) only.
MDCO' s 10-Year ROA (%) Range
Min: -183.56  Med: -4.54 Max: 24.65
Current: -1.16
-183.56
24.65
ROC (Joel Greenblatt) (%) -31.22
MDCO's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. MDCO: -31.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16443.26  Med: -60.11 Max: 402.9
Current: -31.22
-16443.26
402.9
Revenue Growth (3Y)(%) 8.10
MDCO's Revenue Growth (3Y)(%) is ranked higher than
54% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MDCO: 8.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDCO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 10.00 Max: 88.9
Current: 8.1
0
88.9
EBITDA Growth (3Y)(%) -52.10
MDCO's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. MDCO: -52.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -33.90 Max: -7.9
Current: -52.1
» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MDCO Guru Trades in Q3 2014

Vanguard Health Care Fund 4,762,730 sh (+1.33%)
Chuck Royce 6,729,175 sh (+1.10%)
George Soros Sold Out
RS Investment Management 477,466 sh (-1.52%)
Joel Greenblatt 24,009 sh (-87.68%)
» More
Q4 2014

MDCO Guru Trades in Q4 2014

Steven Cohen 221,600 sh (New)
Vanguard Health Care Fund 5,461,430 sh (+14.67%)
Joel Greenblatt Sold Out
RS Investment Management 476,998 sh (-0.10%)
Chuck Royce 4,647,740 sh (-30.93%)
Chuck Royce 4,647,740 sh (-30.93%)
» More
Q1 2015

MDCO Guru Trades in Q1 2015

Paul Tudor Jones 9,000 sh (New)
Steven Cohen 273,500 sh (+23.42%)
Vanguard Health Care Fund 5,564,220 sh (+1.88%)
RS Investment Management 338,358 sh (-29.07%)
Chuck Royce 2,081,370 sh (-55.22%)
» More
Q2 2015

MDCO Guru Trades in Q2 2015

Chuck Royce 202,932 sh (-90.25%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 97.09
MDCO's Forward P/E is ranked lower than
91% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. MDCO: 97.09 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.21
MDCO's P/B is ranked higher than
68% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MDCO: 2.21 )
Ranked among companies with meaningful P/B only.
MDCO' s 10-Year P/B Range
Min: 1.14  Med: 2.51 Max: 8.5
Current: 2.21
1.14
8.5
P/S 3.22
MDCO's P/S is ranked higher than
52% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. MDCO: 3.22 )
Ranked among companies with meaningful P/S only.
MDCO' s 10-Year P/S Range
Min: 0.9  Med: 2.76 Max: 10.46
Current: 3.22
0.9
10.46
POCF 65.47
MDCO's POCF is ranked lower than
76% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. MDCO: 65.47 )
Ranked among companies with meaningful POCF only.
MDCO' s 10-Year POCF Range
Min: 8.63  Med: 25.61 Max: 296.67
Current: 65.47
8.63
296.67
Shiller P/E 51.89
MDCO's Shiller P/E is ranked lower than
63% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. MDCO: 51.89 )
Ranked among companies with meaningful Shiller P/E only.
MDCO' s 10-Year Shiller P/E Range
Min: 25.91  Med: 51.76 Max: 748.5
Current: 51.89
25.91
748.5
Current Ratio 2.51
MDCO's Current Ratio is ranked higher than
54% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MDCO: 2.51 )
Ranked among companies with meaningful Current Ratio only.
MDCO' s 10-Year Current Ratio Range
Min: 0.75  Med: 4.30 Max: 10.09
Current: 2.51
0.75
10.09
Quick Ratio 2.15
MDCO's Quick Ratio is ranked higher than
59% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MDCO: 2.15 )
Ranked among companies with meaningful Quick Ratio only.
MDCO' s 10-Year Quick Ratio Range
Min: 0.75  Med: 3.68 Max: 9.44
Current: 2.15
0.75
9.44
Days Inventory 130.90
MDCO's Days Inventory is ranked lower than
59% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. MDCO: 130.90 )
Ranked among companies with meaningful Days Inventory only.
MDCO' s 10-Year Days Inventory Range
Min: 15.56  Med: 131.57 Max: 1606.52
Current: 130.9
15.56
1606.52
Days Sales Outstanding 53.87
MDCO's Days Sales Outstanding is ranked higher than
65% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. MDCO: 53.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDCO' s 10-Year Days Sales Outstanding Range
Min: 26.9  Med: 50.22 Max: 156.75
Current: 53.87
26.9
156.75

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.95
MDCO's Price/Projected FCF is ranked higher than
66% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. MDCO: 1.95 )
Ranked among companies with meaningful Price/Projected FCF only.
MDCO' s 10-Year Price/Projected FCF Range
Min: 0.84  Med: 1.51 Max: 11.15
Current: 1.95
0.84
11.15
Price/Median PS Value 1.17
MDCO's Price/Median PS Value is ranked higher than
64% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MDCO: 1.17 )
Ranked among companies with meaningful Price/Median PS Value only.
MDCO' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.36 Max: 65.44
Current: 1.17
0.35
65.44
Earnings Yield (Greenblatt) (%) -1.11
MDCO's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. MDCO: -1.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDCO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.11  Med: 3.20 Max: 15.2
Current: -1.11
-1.11
15.2
Forward Rate of Return (Yacktman) (%) -16.78
MDCO's Forward Rate of Return (Yacktman) (%) is ranked lower than
88% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. MDCO: -16.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDCO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -16.8  Med: 1.90 Max: 5.2
Current: -16.78
-16.8
5.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany,
The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Netflix Profit Above Consensus, Panera Bread Boosts Buyback Plan, Medicines Co Cangrelor Well-Recomm Apr 16 2015 
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 

More From Other Websites
What's in Store for Hospira (HSP) this Earnings Season? - Analyst Blog Jul 27 2015
Regeneron Cholesterol Fighter Wins FDA OK, With Conditions Jul 24 2015
Will Express Scripts (ESRX) Miss Earnings Estimates in Q2? - Analyst Blog Jul 24 2015
Looking At Newly Owned Activist Stocks Jul 23 2015
Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog Jul 21 2015
Can Bristol-Myers (BMY) Keep its Earnings Streak Alive? - Analyst Blog Jul 21 2015
Will AmerisourceBergen (ABC) Disappoint Earnings in Q3? - Analyst Blog Jul 21 2015
Hospira (HSP) Launches Generic Angiomax in the U.S. - Analyst Blog Jul 17 2015
Will Novartis (NVS) Disappoint Q2 Earnings due to Generics? - Analyst Blog Jul 17 2015
The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and... Jul 15 2015
4 Health Care Stocks to Watch Out for this Earnings Season - Earnings ESP Jul 14 2015
The Medicines Company to Announce Second Quarter Financial Results on Wednesday July 29, 2015 Jul 13 2015
The Medicines Company to Announce Second Quarter Financial Results on Wednesday July 29, 2015 Jul 13 2015
Can The Medicines Company (MDCO) Run Higher on Strong Earnings Estimate Revisions? - Tale of the... Jul 10 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin) Jul 09 2015
MEDICINES CO /DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Jul 09 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin) Jul 09 2015
Zacks Investment Ideas feature highlights: Tempur Sealy, Medicines Co and Interactive Brokers -... Jul 08 2015
Biotech Stock Roundup: Vertex CF Drug Approved, Biogen Strikes Deal for Gene Therapy - Analyst Blog Jul 08 2015
Why the Earnings Streak Will Continue for The Medicines Company (MDCO) - Tale of the Tape Jul 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK